Mosaic drug discovery platform is the first to make in vivo data generation scalable, with single-cell precision; resulting datasets will be the world's largest atlas of how drugs interact with patient cells. This approach combines an atlas with AI models to capture in vivo context of disease early in discovery and better represent patient diversity in drug response over current in vitro assays. The company is backed by prominent investors and founded by pioneers at the intersection of life sciences and technology, including co-founder Kevan Shokat, PhD.
